120 related articles for article (PubMed ID: 15585451)
21. Hospital-acquired pneumonia in critically ill patients: factors associated with episodes due to imipenem-resistant organisms.
Leroy O; d'Escrivan T; Devos P; Dubreuil L; Kipnis E; Georges H
Infection; 2005 Jun; 33(3):129-35. PubMed ID: 15940413
[TBL] [Abstract][Full Text] [Related]
22. Healthcare-associated infections. A useful concept?
Lujan M; Gallego M; Rello J
Curr Opin Crit Care; 2009 Oct; 15(5):419-24. PubMed ID: 19553808
[TBL] [Abstract][Full Text] [Related]
23. Antimicrobial activity of tigecycline tested against organisms causing community-acquired respiratory tract infection and nosocomial pneumonia.
Fritsche TR; Sader HS; Stilwell MG; Dowzicky MJ; Jones RN
Diagn Microbiol Infect Dis; 2005 Jul; 52(3):187-93. PubMed ID: 16105563
[TBL] [Abstract][Full Text] [Related]
24. Efficacy and safety evaluation of fixed dose combination of cefepime and amikacin in comparison with cefepime alone in treatment of nosocomial pneumonia patients.
Chaudhary M; Shrivastava SM; Varughese L; Sehgal R
Curr Clin Pharmacol; 2008 May; 3(2):118-22. PubMed ID: 18700304
[TBL] [Abstract][Full Text] [Related]
25. The epidemiology of bacteremia with febrile neutropenia: experience from a single center, 1988-2004.
Paul M; Gafter-Gvili A; Leibovici L; Bishara J; Levy I; Yaniv I; Shalit I; Samra Z; Pitlik S; Konigsberger H; Weinberger M
Isr Med Assoc J; 2007 Jun; 9(6):424-9. PubMed ID: 17642387
[TBL] [Abstract][Full Text] [Related]
26. What is healthcare-associated pneumonia and how is it managed?
Carratalà J; Garcia-Vidal C
Curr Opin Infect Dis; 2008 Apr; 21(2):168-73. PubMed ID: 18317041
[TBL] [Abstract][Full Text] [Related]
27. Experience with cefepime versus meropenem as empiric monotherapy for neutropenia and fever in pediatric patients with solid tumors.
Oguz A; Karadeniz C; Citak EC; Cil V; Eldes N
Pediatr Hematol Oncol; 2006; 23(3):245-53. PubMed ID: 16517540
[TBL] [Abstract][Full Text] [Related]
28. Impact of antibiotic-resistant bacteria on the outcome of ventilator-associated pneumonia.
Combes A; Luyt CE; Trouillet JL
Semin Respir Crit Care Med; 2006 Feb; 27(1):23-8. PubMed ID: 16508878
[TBL] [Abstract][Full Text] [Related]
29. Rational empiric antibiotic prescription in the ICU.
Singh N; Yu VL
Chest; 2000 May; 117(5):1496-9. PubMed ID: 10807841
[TBL] [Abstract][Full Text] [Related]
30. Update on the treatment of Pseudomonas aeruginosa pneumonia.
El Solh AA; Alhajhusain A
J Antimicrob Chemother; 2009 Aug; 64(2):229-38. PubMed ID: 19520717
[TBL] [Abstract][Full Text] [Related]
31. Effects of an alternative cefepime dosing strategy in pulmonary and bloodstream infections caused by Enterobacter spp, Citrobacter freundii, and Pseudomonas aeruginosa: a single-center, open-label, prospective, observational study.
Deal EN; Micek ST; Reichley RM; Ritchie DJ
Clin Ther; 2009 Feb; 31(2):299-310. PubMed ID: 19302902
[TBL] [Abstract][Full Text] [Related]
32. Prophylaxis and treatment of bacterial infections: do we need new strategies?
Micozzi A; Bucaneve G
Rev Clin Exp Hematol; 2005 Dec; 9(2):E4. PubMed ID: 16864118
[TBL] [Abstract][Full Text] [Related]
33. Possible clinical indications of ceftobiprole.
Barberán J
Rev Esp Quimioter; 2019 Sep; 32 Suppl 3(Suppl 3):29-33. PubMed ID: 31364339
[TBL] [Abstract][Full Text] [Related]
34. Impact of an institution-specific hospital-acquired pneumonia protocol on the appropriateness of antibiotic therapy and patient outcomes.
Lancaster JW; Lawrence KR; Fong JJ; Doron SI; Garpestad E; Nasraway SA; Devlin JW
Pharmacotherapy; 2008 Jul; 28(7):852-62. PubMed ID: 18576900
[TBL] [Abstract][Full Text] [Related]
35. Monotherapy versus combination therapy.
Patel SM; Saravolatz LD
Med Clin North Am; 2006 Nov; 90(6):1183-95. PubMed ID: 17116443
[TBL] [Abstract][Full Text] [Related]
36. Reduction in inadequate empiric antibiotic therapy for ventilator-associated pneumonia: impact of a unit-specific treatment pathway.
Magnotti LJ; Schroeppel TJ; Fabian TC; Clement LP; Swanson JM; Fischer PE; Bee TK; Maish GO; Minard G; Zarzaur BL; Croce MA
Am Surg; 2008 Jun; 74(6):516-22; discussion 522-3. PubMed ID: 18556994
[TBL] [Abstract][Full Text] [Related]
37. The intensive care unit in antimicrobial resistance.
Koleff MH
Postgrad Med; 2001 Feb; 109(2 Suppl):60-9. PubMed ID: 19667559
[TBL] [Abstract][Full Text] [Related]
38. Cefepime monotherapy is as effective as ceftriaxone plus amikacin in pediatric patients with cancer and high-risk febrile neutropenia in a randomized comparison.
Pereira CA; Petrilli AS; Carlesse FA; Luisi FA; da Silva KV; de Martino Lee ML
J Microbiol Immunol Infect; 2009 Apr; 42(2):141-7. PubMed ID: 19597646
[TBL] [Abstract][Full Text] [Related]
39. Cefepime plus amikacin as an initial empirical therapy of febrile neutropenia in paediatric cancer patients.
Hamidah A; Lim YS; Zulkifli SZ; Zarina AL; Nordiah AJ; Jamal R
Singapore Med J; 2007 Jul; 48(7):615-9. PubMed ID: 17609821
[TBL] [Abstract][Full Text] [Related]
40. Nosocomial bacterial pneumonia in HIV-infected patients: risk factors for adverse outcome and implications for rational empiric antibiotic therapy.
Franzetti F; Grassini A; Piazza M; Degl'innocenti M; Bandera A; Gazzola L; Marchetti G; Gori A
Infection; 2006 Feb; 34(1):9-16. PubMed ID: 16501896
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
